Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-24 @ 10:49 PM
Ignite Modification Date:
2025-12-25 @ 8:18 PM
NCT ID:
NCT03801369
Group ID:
EG000
Title:
Arm I (olaparib, durvalumab)
Description:
Patients receive olaparib PO BID on days 1-28 of each cycle and durvalumab intravenously (IV) over 1 hour on day 1 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients deriving clinical benefit from treatment may, at the investigator's discretion and in the absence of disease progression or unacceptable toxicity, continue on therapy beyond the planned 13 cycles.
Biopsy: Undergo biopsy
Durvalumab: Given IV (infusion)
Olaparib: Given PO (orally)
Quality-of-Life Assessment: Ancillary studies
Deaths Number Affected:
19
Deaths Number At Risk:
None
Serious Number Affected:
2
Serious Number At Risk:
24
Other Number Affected:
24
Other Number At Risk:
24
Study:
NCT03801369
Results Section:
NCT03801369
Adverse Events Module:
NCT03801369